Novacyt Group acquires Southern Cross Diagnostics

Novacyt Group agreed to acquire Southern Cross Diagnostics. Reported deal value: Undisclosed. Status: Announced. Sector: clinical diagnostics. Target headquarters context: Banksmeadow, New South Wales, Australia.

This page summarizes publicly available information about the transaction as of 2026-02-23. Figures and status may change as filings and press coverage update.

Volume:46,180 MM 20 0 : n/a Novacyt announced on Monday that it has conditionally agreed to acquire Southern Cross Diagnostics for an initial cash consideration of AUD 8.5m , as the molecular diagnostics group looked to expand its footprint in the fast-growing Australian market and accelerate its path to profitability